Orphan Therapeutics, LLC is a privately held drug development company. It was founded in 2003 with the purpose to develop and seek regulatory approval for its first product, Lucassin® (terlipressin), for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US, Canada, Japan and Australia. In March 2010, Orphan Therapeutics sold the New Drug Application (NDA) and its development rights for Lucassin® in North America and Australia to its Commercialization Partner Ikaria Inc., with a continued commitment to assist the Ikaria team through the FDA approval process.
